Cancer Advisor

Computed tomography (CT) and magnetic resonance imaging (MRI) scans have revolutionized modern medicine, enabling doctors to detect cancers, infections, vascular diseases, and internal injuries with remarkable accuracy. In many cases, these scans are performed using contrast agents, special substances injected into the bloodstream to improve image quality and diagnostic precision. While contrast-enhanced imaging is generally considered safe, growing public awareness and scientific discussion have raised important questions about potential side effects, long-term tissue retention, kidney safety, and informed consent. Understanding both the benefits and risks can help patients make informed decisions before undergoing a contrast-enhanced CT or MRI scan. What Is Contrast Material? Contrast agents are pharmaceutical substances administered before or during imaging studies to improve visualization of organs, blood vessels, and abnormal tissues. There are two major types: Iodinated...

Last revised: June 2026 Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Ivermectin combined with benzimidazoles (fenbendazole, mebendazole) represents an emerging area of repurposed oncology pharmacology. All protocols require physician supervision. Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dos...

Understanding PET scan responses, tumor biology, and how “metabolic response” has become a key cancer treatment endpoint Introduction In modern oncology, treatment success is no longer judged only by whether a tumor shrinks on a CT scan. A deeper concept has become increasingly important: Metabolic response — the change in cancer cell activity, not just tumor size. This shift comes from advances in PET imaging , which can detect cancer activity at a cellular energy level long before anatomical changes appear. Understanding metabolic response is essential for interpreting: Chemotherapy outcomes Immunotherapy results Targeted therapy effectiveness And even controversial or experimental treatment reports. What Is Metabolic Response in Cancer? A metabolic response refers to changes in how active cancer cells are, typically measured using a PET (Positron Emission Tomography) scan . Most commonly, PET scans use a tracer called FDG (fluorodeoxyglucose) , a radioactive form of glucose. Cancer...

Daraxonrasib (RMC-6236) nearly doubles median survival in previously treated metastatic pancreatic cancer (13.2 vs. 6.7 months) with a 60% reduction in death risk. Learn about the breakthrough RAS(ON) inhibitor, side effects, trial results, cost concerns, and what it means for patients in 2026. Pancreatic cancer remains one of the deadliest cancers, with a 5-year survival rate under 13% overall and just 3% for metastatic disease. But in May 2026, a new oral pill called daraxonrasib (also known as RMC-6236) delivered what experts are calling “historic” and “practice-changing” results.In the pivotal Phase 3 RASolute 302 trial, daraxonrasib doubled median overall survival and cut the risk of death by 60% compared to standard chemotherapy — all while being better tolerated for many patients.  Here’s everything you need to know about this groundbreaking pancreatic cancer treatment, including the science, real-world implications, side effects, cost debates, and expert perspectives. What ...